{"id":66,"date":"2026-07-28T18:22:25","date_gmt":"2026-07-28T18:22:25","guid":{"rendered":"https:\/\/empyreanbiolab.wpenginepowered.com\/?post_type=product&#038;p=66"},"modified":"2026-09-01T11:45:11","modified_gmt":"2026-09-01T11:45:11","slug":"retatrutide","status":"publish","type":"product","link":"https:\/\/empyreanbiolabsusa.com\/?product=retatrutide","title":{"rendered":"Retatrutide"},"content":{"rendered":"<p class=\"\" data-start=\"603\" data-end=\"1061\">Retatrutide is a first-in-class triple hormone receptor agonist developed to activate three major metabolic pathways: glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptors. By bringing all three mechanisms together within a single molecule, Retatrutide is designed to influence appetite, satiety, glucose-dependent insulin signaling, nutrient metabolism, energy expenditure, and the way the body manages stored energy.<\/p>\n<p data-start=\"1063\" data-end=\"1442\">GLP-1 and GIP receptor activity supports fullness, appetite regulation, and glucose-dependent insulin response, while glucagon-receptor activity adds a distinct pathway associated with energy expenditure and lipid metabolism. This coordinated triple-agonist design has made Retatrutide one of the most closely watched compounds in modern metabolic and weight-management research.<\/p>\n<p data-start=\"1444\" data-end=\"2227\">In the published Phase 2 obesity trial, once-weekly Retatrutide produced substantial, dose-dependent body-weight reductions over 48 weeks. More recently, Lilly reported positive topline results from the pivotal Phase 3 TRIUMPH-1 trial: participants receiving the highest studied dose lost an average of 28.3% of their starting body weight at 80 weeks. A prespecified extension involving participants with higher starting BMIs reported an average reduction of 30.3% at 104 weeks. Improvements were also reported in waist circumference, triglycerides, non-HDL cholesterol, systolic blood pressure, and inflammatory markers. The Phase 3 findings are company-reported topline results and should be distinguished from fully peer-reviewed publication.<\/p>\n<p data-start=\"2229\" data-end=\"2731\">Retatrutide is also being studied across a broad metabolic-development program involving obesity, type 2 diabetes, cardiovascular and renal outcomes, obstructive sleep apnea, knee osteoarthritis, chronic lower-back pain, and metabolic dysfunction-associated steatotic liver disease. Its ability to unite appetite control, glucose regulation, and energy-expenditure pathways makes Retatrutide one of the most compelling compounds in contemporary metabolic research.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Retatrutide is a next-generation triple hormone receptor agonist designed to activate GIP, GLP-1, and glucagon receptors within a single molecule. This unique three-pathway approach has generated significant interest in appetite regulation, glucose metabolism, insulin sensitivity, energy expenditure, lipid metabolism, and sustained body-weight reduction. Clinical research has produced powerful results across obesity, metabolic health, and type 2 diabetes studies.<\/p>\n","protected":false},"featured_media":49,"comment_status":"open","ping_status":"closed","template":"","meta":[],"product_brand":[],"product_cat":[27,15,24],"product_tag":[105,106,98,107,103,104,95,100,101,94,99,96,97,102],"class_list":["post-66","product","type-product","status-publish","has-post-thumbnail","product_cat-cellular-metabolic-research","product_cat-uncategorized","product_cat-weight-management-research","product_tag-appetite-regulation-research","product_tag-energy-expenditure-research","product_tag-gip-glp-1-glucagon-agonist","product_tag-glucagon-receptor-research","product_tag-glucose-metabolism-research","product_tag-insulin-sensitivity-research","product_tag-ly3437943","product_tag-metabolic-research","product_tag-obesity-research","product_tag-retatrutide","product_tag-retatrutide-research","product_tag-triple-agonist","product_tag-triple-hormone-receptor-agonist","product_tag-weight-management-research","first","instock","shipping-taxable","purchasable","product-type-variable"],"_links":{"self":[{"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=\/wp\/v2\/product\/66","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=\/wp\/v2\/product"}],"about":[{"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=\/wp\/v2\/media\/49"}],"wp:attachment":[{"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_brand&post=66"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_cat&post=66"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/empyreanbiolabsusa.com\/index.php?rest_route=%2Fwp%2Fv2%2Fproduct_tag&post=66"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}